Back to All Combinations

TP53 Mutated (RAS WT)

Intermediate Prognosis
15.00% Prevalence Level 3 TP53 Combinations
Genes Involved
TP53
Treatment Implications

Does not preclude anti-EGFR if RAS/BRAF wild-type.

Recommended Treatments
Anti-EGFR therapy
Standard chemotherapy
Treatments to Avoid

No specific contraindications noted

Study References

TCGA

Key Statistics
15.00%
Prevalence in CRC
No
Targetable
Clinical Notes
Prognosis depends on co-mutations.
Information

Category: TP53 Combinations

Evidence Level: Level 3

Last Updated: Dec 7, 2025

Related Combinations
Medical Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Always consult with your oncologist for personalized treatment decisions based on your specific situation.